148404-29-9

Usage

Uses

Used in Pharmaceutical Industry:
Benzyl 5-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate is used as a pharmaceutical agent for its demonstrated antibacterial, antifungal, and antiviral properties. It is valued for its potential to combat a range of infections and diseases, offering a new avenue for drug development in the medical field.
Used in Drug Development:
In the realm of drug development, benzyl 5-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate is utilized as a lead compound for the creation of new medications. Its biological activities suggest that it could be a key component in the formulation of drugs targeting various pathogens and conditions.
Used in Medical Research:
Benzyl 5-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate is also used as a subject of medical research to explore its mechanisms of action and potential synergistic effects with other compounds. This research is crucial for understanding how to best harness its properties for therapeutic use.
While the provided materials do not specify different industries for the uses of benzyl 5-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate, the primary focus is on its applications within the pharmaceutical sector. Further exploration into its applications may reveal additional uses in various industries as research progresses.

Upstream product

• 144734-57-6 benzyl allyl(prop-2-yn-1-yl)carbamate 
• 15226-74-1 dicobalt octacarbonyl 
• 96896-09-2 (3aR,6aS)-hexahydrocyclopenta[c]pyrrol-5(1H)-one 
• 501-53-1 benzyl chloroformate 
• 42268-68-8 allylpropargylamine 
• 5041-33-8 N-(Benzyloxycarbonyl)allylamine 
• 1469-48-3 cis-1,2,3,6-Tetrahydrophthalimide 
• 2144-87-8 (cis)-2,3,3a,4,7,7a-hexahydro-1H-isoindole 

Relevant academic research and scientific papers

Octahydrocyclopenta[c]pyrrole Allosteric Inhibitors of SHP2

The present invention relates to compounds capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds, and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B

Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed. Such diseases include, without limitation, neurological dysfunction such as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, and seizure disorders; emotional disorders; depression; bipolar disorder; obsessive-compulsive disorder; and other anxiety disorders.

PYRROLE SIX-MEMBERED HETEROARYL RING DERIVATIVE, PREPARATION METHOD THEREOF, AND MEDICINAL USES THEREOF

The present invention relates to a pyrrole six-membered heteroaryl ring derivative, the preparation method therefor, and the medicinal uses thereof. Specifically, the present invention relates to a new pyrrole six-membered herteroaryl ring derivative as r

PYRROLE SIX-MEMBERED HETEROARYL RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICINAL USES THEREOF

The present invention relates to a pyrrole six-membered heteroaryl ring derivative, the preparation method therefor, and the medicinal uses thereof. Specifically, the present invention relates to a new pyrrol six-membered herteroaryl ring derivative as re

Studies of the solid-phase Pauson-Khand reaction: Selective in-situ enone reduction to 3-azabicyclo[3.3.0] octanones

The Smit-Caple DSAC Pauson-Khand cyclization of a series of N-protected allyl propargyl amines in the absence of oxygen gave rise to formation of the saturated azabicyclo[3.3.0]octanones in excellent yields. Standard cyclization in air gave mixtures of sa